首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1057篇
  免费   41篇
  国内免费   30篇
耳鼻咽喉   1篇
儿科学   5篇
妇产科学   2篇
基础医学   47篇
口腔科学   15篇
临床医学   98篇
内科学   99篇
皮肤病学   10篇
神经病学   17篇
特种医学   18篇
外科学   208篇
综合类   193篇
预防医学   155篇
眼科学   1篇
药学   200篇
  2篇
中国医学   51篇
肿瘤学   6篇
  2024年   4篇
  2023年   10篇
  2022年   38篇
  2021年   41篇
  2020年   18篇
  2019年   20篇
  2018年   23篇
  2017年   17篇
  2016年   18篇
  2015年   37篇
  2014年   53篇
  2013年   109篇
  2012年   41篇
  2011年   81篇
  2010年   57篇
  2009年   55篇
  2008年   62篇
  2007年   58篇
  2006年   48篇
  2005年   43篇
  2004年   35篇
  2003年   39篇
  2002年   21篇
  2001年   37篇
  2000年   19篇
  1999年   27篇
  1998年   8篇
  1997年   14篇
  1996年   7篇
  1995年   8篇
  1994年   8篇
  1993年   4篇
  1992年   6篇
  1991年   10篇
  1990年   8篇
  1989年   6篇
  1988年   8篇
  1987年   5篇
  1986年   5篇
  1985年   6篇
  1984年   3篇
  1983年   2篇
  1982年   1篇
  1979年   2篇
  1978年   1篇
  1975年   1篇
  1973年   4篇
排序方式: 共有1128条查询结果,搜索用时 78 毫秒
951.
羟乙基淀粉130/0.4的研究进展   总被引:7,自引:0,他引:7  
羟乙基淀粉130/0.4是一种新型的羟乙基淀粉代血浆产品, 国外已用于临床.重点综述了羟乙基淀粉130/0.4的扩容作用、药动学、安全性评价和临床研究.  相似文献   
952.
目的:建立盐酸小檗碱片、格列吡嗪片、卡马西平片、盐酸雷尼替丁胶囊、茶碱缓释片、对乙酰氨基酚片6种口服固体制剂中淀粉类辅料含量的"逆向工程"分析方法。方法:口服固体制剂经有机溶剂提取去除干扰成分,采用碘溶液(称取碘1.3 g、碘化钾3.6 g加水溶解稀释至100 mL)显色后,在可见波长575 nm处测定吸光度。结果:淀粉浓度在20.288~71.008 μg·mL-1范围内线性关系良好(r=0.999),6种口服固体制剂的方法回收率均在85%~110%(n=9,RSD不超过5.0%),重复性(n=6)RSD均小于5.0%。结论:所建立的淀粉类辅料含量测定方法准确、可靠、操作方便,适合用于口服固体制剂中淀粉、玉米淀粉、预胶化淀粉等辅料的含量测定。  相似文献   
953.
Dietary advice constitutes a treatment strategy for irritable bowel syndrome (IBS). We aimed to examine the effect of a starch- and sucrose-reduced diet (SSRD) on gastrointestinal symptoms in IBS patients, in relation to dietary intake and systemic inflammatory parameters. IBS patients (n = 105) were randomized to a 4-week SSRD intervention (n = 80) receiving written and verbal dietary advice focused on starch and sucrose reduction and increased intake of protein, fat and dairy, or control group (n = 25; habitual diet). At baseline and 4 weeks, blood was sampled, and participants filled out IBS-SSS, VAS-IBS, and Rome IV questionnaires and dietary registrations. C-reactive protein and cytokines TNF-α, IFN-γ, IL-6, IL-8, IL-10, and IL-18 were analyzed from plasma. At 4 weeks, the intervention group displayed lower total IBS-SSS, ‘abdominal pain’, ‘bloating/flatulence’ and ‘intestinal symptoms´ influence on daily life’ scores (p ≤ 0.001 for all) compared to controls, and a 74%, responder rate (RR = ΔTotal IBS-SSS ≥ −50; RRcontrols = 24%). Median values of sucrose (5.4 vs. 20 g), disaccharides (16 vs. 28 g), starch (22 vs. 82 g) and carbohydrates (88 vs. 182 g) were lower for the intervention group compared to controls (p ≤ 0.002 for all), and energy percentages (E%) of protein (21 vs. 17 E%, p = 0.006) and fat (47 vs. 38 E%, p = 0.002) were higher. Sugar-, starch- and carbohydrate-reductions correlated weakly-moderately with total IBS-SSS decrease for all participants. Inflammatory parameters were unaffected. IBS patients display high compliance to the SSRD, with improved gastrointestinal symptoms but unaltered inflammatory parameters. In conclusion, the SSRD constitutes a promising dietary treatment for IBS, but needs to be further researched and compared to established dietary treatments before it could be used in a clinical setting.  相似文献   
954.
It is well known that carriers can affect the dissolution of poorly soluble drugs. In this study, our aim was to investigate the dissolution enhancement of carbamazepine solid dispersed or mixed at different loading ratios in crospovidone, polyvinylpyrrolidone, and sodium starch glycolate. The physical state of the drug and the drug–polymer interactions in the solid state were investigated using differential scanning calorimetry (DSC) and x-ray diffraction analysis (XRD). Through the solubilization kinetics and dissolution rates studies, the in vitro drug availability of the systems was evaluated. An improved in vitro dissolution of the drug was obtained in all the binary systems that increased as the polymer content increased.  相似文献   
955.
The effect of hydroxyethyl methylcellulose (HEMC) with different viscosities on the glucose metabolism and antioxidative defense system in high fat-fed mice was investigated. The mice were randomly divided into five dietary groups: normal control diet (NC), high fat diet (HF), and high fat diet supplemented with high viscosity (HF-HV), moderate viscosity (HF-MV), and low viscosity (HF-LV) HEMC fibers. After 6 weeks, the HF group showed a marked increase in body weight gain, body fat, blood glucose concentration, insulin level, and erythrocyte lipid peroxidation rate relative to the NC group. However, supplementation of HEMC in the diet suppressed these high fat-induced hyperglycemia and oxidative stress through enhancement of the activities of hepatic glucokinase and antioxidant enzymes. The hypoglycemic and antioxidative effects increased with increased viscosity of the HEMC consumed. These results illustrate that HEMC with high viscosity may be useful in the management of high fat diet-induced hyperglycemia and oxidative stress.  相似文献   
956.
10-Hydroxy camptothecin (10-HCPT) is an antitumor agent effective in the treatment of several solid tumors but its use is hampered by poor water solubility, low lactone stability, short plasma half-life and dose-limiting toxicity. These limits of 10-HCPT had been overcome by our group through preparing super macromolecule prodrug: 10-HCPT-hydroxyethyl starch (HES) conjugate. In this study, we mainly evaluated in vitro and in vivo behavior of the prodrug, containing cytotoxicity assay, pharmacodynamics study, vascular irritation test, hemolysis experiment and tissue distribution test of rats. The irritation test results achieved much lower irritation than the commercial injection. The tissue distribution results showed that HES-10-HCPT conjugate increased significantly the 10-HCPT concentration in the tumor, liver and spleen site, whereas decreased the drug concentration in the heart and kidney. The hemolysis effect of the prepared conjugate was not obvious. The pharmacodynamics results indicated that HES-10-HCPT prodrug had a better antitumor efficiency against mice with H22 tumor than the commercial injection, and the inhibition ratio of tumor was 85.2% and 31.1%, respectively at the same dosage. These findings suggest that HES-10-HCPT prodrug is a promising drug delivery system providing improved good injection safety, greater tolerance and antitumor effect.  相似文献   
957.
目的对气相色谱法(GC)测定羟乙基淀粉摩尔取代度进行研究。方法色谱柱为DB-624石英毛细管柱(L=60 m,=0.53 mm),FID检测器;进样口温度为200℃,检测器温度为280℃;柱温采用程序升温,载气为氮气,流速为8 mL.min-1,分流比为1∶20。以甲苯为内标物。结果对照品碘乙烷在0.30~2.1 mg.mL-1(r=0.999 9)范围内呈良好线性关系。反应温度、时间对测定结果影响显著,最佳反应条件为135℃反应15 h;样品水分、氯化钠含量对测定结果无影响。结论该方法测定结果准确,简便快捷,适合羟乙基淀粉摩尔取代度的测定。  相似文献   
958.
在程控和直接存放于-80℃冰箱两种降温方式下,采用联合冷冻保护液(5%二甲基亚砜+60g/L羟乙基淀粉+40g/L(白蛋白)冷冻保护人骨髓细胞,并与传统冷冻保护液(10%二甲基亚砜+10%人血清)相比较。结果,粒细脑─巨噬细胞集落的回收率各组间的差异不显著,但在室温下,前者对造血细胞增殖能力的抑制较小。此外,直接存放于-80℃冰箱可代替程控降温,前者具有简便、易规范化的特点。这些结果有利于我国骨髓移植工作的开展。  相似文献   
959.
This study deals with the production of starch microspheres containing insulin using the sonochemical technique. The structure and properties of the final product were studied using SEM, FTIR and XRD. A microsphere size of 600 nm and the size distribution of the starch microspheres with encapsulated insulin were determined. A spectrophotometric analytical procedure was selected to evaluate the amount of loaded insulin in the starch microspheres and to perform the release studies. The product is organized in a double‐layer structure (insulin layer covered by starch layer), and this composite may provide a new system for the administration of protein drugs. The microspherilization process involves the degradation of the starch to the smaller fragments due to the application of high‐intensity ultrasound, and the organization of these fragments in a microsphere structure using the same type of bonds as in regular starch.

  相似文献   

960.
《Nutrition reviews》1987,45(10):234-236
The direct infusion of raw wheat starch into the human colon has shown that the colon plays a role in the fermentation of starch as well as fiber  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号